|1.||Freedman, Mark S: 11 articles (10/2014 - 10/2011)|
|2.||Kappos, Ludwig: 9 articles (05/2015 - 10/2011)|
|3.||Truffinet, Philippe: 9 articles (04/2015 - 10/2011)|
|4.||Miller, Aaron E: 7 articles (10/2015 - 11/2012)|
|5.||Comi, Giancarlo: 7 articles (10/2014 - 10/2011)|
|6.||Olsson, Tomas P: 7 articles (10/2014 - 10/2011)|
|7.||O'Connor, Paul W: 7 articles (10/2014 - 09/2012)|
|8.||Wolinsky, Jerry S: 7 articles (10/2014 - 10/2011)|
|9.||Confavreux, Christian: 6 articles (05/2014 - 10/2011)|
|10.||Bar-Or, Amit: 5 articles (04/2015 - 09/2012)|
09/01/2012 - "Teriflunomide, an oral disease-modifying therapy in development for patients with relapsing forms of multiple sclerosis (RMS), was well tolerated and effective in reducing magnetic resonance imaging (MRI) lesions in 179 RMS patients in a phase 2 36-week, placebo-controlled study. "
03/28/2006 - "Oral teriflunomide was effective in reducing MRI lesions and was well tolerated in patients with relapsing multiple sclerosis."
05/01/2015 - "Teriflunomide is a new oral disease-modifying drug (DMD), recently approved for the first-line treatment of relapsing multiple sclerosis (MS). "
12/01/2011 - "Multiple sclerosis: Teriflunomide shows promise for MS treatment in phase III trial."
03/28/2006 - "In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses. "
|2.||Relapsing-Remitting Multiple Sclerosis
02/01/2015 - "Teriflunomide, a once-daily, oral disease-modifying therapy, is a valuable new treatment option for the management of patients with relapsing-remitting multiple sclerosis. "
12/01/2014 - "Teriflunomide, indicated for the treatment of relapsing-remitting multiple sclerosis, is contraindicated in pregnancy based on signs of developmental toxicity in the offspring of rats and rabbits; developmental toxicity has also been observed in preclinical studies of other disease-modifying therapies. "
05/01/2015 - "Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis."
02/01/2015 - "Teriflunomide for the treatment of relapsing-remitting multiple sclerosis."
01/01/2015 - "Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence."
|3.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
11/01/2010 - "Therapeutic efficacy of teriflunomide has been demonstrated in vivo in an experimental autoimmune encephalomyelitis model of MS using Dark Agouti rats. "
10/01/2013 - "Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis."
01/01/2013 - "To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. "
01/01/2013 - "Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis."
01/01/2009 - "We report here for the first time the anti-inflammatory effects of teriflunomide in the Dark Agouti rat model of experimental autoimmune encephalomyelitis (EAE). "
|4.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
03/01/2014 - "Intravenous immunoglobulins (IVIG) have demonstrated short- and long-term beneficial effects in CIDP but are not effective in MS. Dimethyl fumarate (BG-12), teriflunomide and laquinimod are orally administered immunomodulatory drugs that are already approved or likely to be approved in the near future for the basic therapy of patients with relapsing-remitting MS (RRMS) due to positive results in Phase III clinical trials. "
05/15/2011 - "The procedure was applied to assess total and free plasma concentrations of teriflunomide in patients with rheumatoid arthritis. "
05/15/2011 - "Therefore, we aimed to develop and validate an LC-MS/MS method for the measurement of teriflunomide, and use it to determine the total and free teriflunomide concentration in patients with rheumatoid arthritis. "
01/01/2009 - "With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed."
01/01/2012 - "Leflunomide is the prodrug of teriflunomide which is the latest compound that has successfully been tested in a large phase III clinical trial in relapsing MS. Due to its favorable safety profile and its efficacy in rheumatoid arthritis where the aberrant immune response is in various aspects similar to the autoimmune reaction in MS patients, teriflunomide is a promising treatment option for MS patients. "
01/01/2016 - "Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) treatment, yet approximately 20 to 40% of patients cease due to toxicity. "
|3.||copolymer 1 (glatiramer acetate)
|5.||Intravenous Immunoglobulins (IVIG)
|5.||Renal Dialysis (Hemodialysis)